InflaRx N.V. (NASDAQ:IFRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has received an average rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.50.

A number of brokerages have recently weighed in on IFRX. HC Wainwright began coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research report on Tuesday, November 11th. Wall Street Zen downgraded shares of InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Guggenheim raised their price objective on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday.

InflaRx Trading Down 3.6%

IFRX opened at $1.08 on Wednesday. The stock has a market capitalization of $72.50 million, a P/E ratio of -1.59 and a beta of 1.46. The stock has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.12. InflaRx has a 12-month low of $0.71 and a 12-month high of $2.77.

InflaRx (NASDAQ:IFRX) last released its earnings results on Monday, November 10th. The company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. On average, equities research analysts predict that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its holdings in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new stake in InflaRx during the 2nd quarter valued at $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after buying an additional 91,927 shares during the period. Susquehanna International Group LLP bought a new stake in InflaRx in the 3rd quarter worth $190,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of InflaRx in the third quarter valued at about $214,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.